Inventor
GUO YANAN
CN42 patents
⚠️ This page may combine multiple inventors who share the name “GUO YANAN”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD
24 patentsUS10973212B2Apr 13, 2021
Genetically modified non-human animal with human or chimeric SIRPa
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD4 citations72
US10912287B2Feb 9, 2021
Genetically modified mice expressing humanized PD-1
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD2 citations71
US12342800B2Jul 1, 2025
Immunodeficient non-human animal
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US12016315B2Jun 25, 2024
Genetically modified non-human animal with human or chimeric CD3e
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US11723348B2Aug 15, 2023
Genetically modified mice expressing humanized CD47
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US11534502B2Dec 27, 2022
Genetically modified non-human animal with human or chimeric TIGIT
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US11497198B2Nov 15, 2022
Genetically modified mice expressing humanized CD40
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US11464876B2Oct 11, 2022
Genetically modified mouse comprising a chimeric TIGIT
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US11439132B2Sep 13, 2022
Humanized transgenic animal
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD1 citations62
US11317611B2May 3, 2022
Genetically modified non-human animal with human or chimeric PD-L1
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US11272695B2Mar 15, 2022
Genetically modified non-human animal with human or chimeric PD-1
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US11240995B2Feb 8, 2022
Genetically modified non-human animal with human or chimeric TIM-3
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US10980222B2Apr 20, 2021
Genetically modified non-human animal with human or chimeric CD27
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US10945420B2Mar 16, 2021
Genetically modified non-human animal with human or chimeric CD3e
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD1 citations62
US10945418B2Mar 16, 2021
Genetically modified non-human animal with human or chimeric PD-L1
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations62
US10925264B2Feb 23, 2021
Genetically modified non-human animal with human or chimeric LAG-3
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD1 citations62
US12180281B2Dec 31, 2024
Anti-PD-1 antibodies and methods of treating cancer
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations61
US11352429B2Jun 7, 2022
Anti-PD-1 antibodies and uses thereof
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD1 citations61
US11350614B2Jun 7, 2022
Genetically modified non-human animal with human or chimeric CD28
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations61
US11154041B2Oct 26, 2021
Genetically modified non-human animal with human or chimeric genes
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations61
US11096383B2Aug 24, 2021
Method of using a genetically modified mouse that expresses a humanized CTLA-4 gene
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations61
US11071290B2Jul 27, 2021
Genetically modified non-human animal with human or chimeric CTLA-4
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations61
US11234420B2Feb 1, 2022
Method for constructing PD-1 gene modified humanized animal model and use thereof
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations60
US11154040B2Oct 26, 2021
Genetically modified non-human animal with human or chimeric CD137
BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD0 citations52
EUCURE BEIJING BIOPHARMA CO LTD
8 patentsUS10934365B2Mar 2, 2021
Anti-OX40 antibodies and uses thereof
EUCURE BEIJING BIOPHARMA CO LTD2 citations71
US12134653B2Nov 5, 2024
Anti-CD40 antibodies and uses thereof
EUCURE BEIJING BIOPHARMA CO LTD0 citations60
US12054547B2Aug 6, 2024
Anti-CTLA4 antibodies and uses thereof
EUCURE BEIJING BIOPHARMA CO LTD0 citations60
US11999790B2Jun 4, 2024
Anti-OX40 antibodies and uses thereof
EUCURE BEIJING BIOPHARMA CO LTD0 citations60
US11142582B2Oct 12, 2021
Anti-CD40 antibodies and uses thereof
EUCURE BEIJING BIOPHARMA CO LTD1 citations60
US11034764B2Jun 15, 2021
Anti-CTLA4 antibodies and uses thereof
EUCURE BEIJING BIOPHARMA CO LTD1 citations60
US11292849B2Apr 5, 2022
Anti-TNFRSF9 antibodies and uses thereof
EUCURE BEIJING BIOPHARMA CO LTD0 citations50
US11155625B2Oct 26, 2021
Anti-PD-1 antibodies and uses thereof
EUCURE BEIJING BIOPHARMA CO LTD0 citations50
BEIJING BIOCYTOGEN CO LTD
3 patentsUS10918095B2Feb 16, 2021
Genetically modified mice expressing humanized CD47
BEIJING BIOCYTOGEN CO LTD5 citations82
US10820580B2Nov 3, 2020
Immunodeficient non-human animal
BEIJING BIOCYTOGEN CO LTD5 citations82
US10945419B2Mar 16, 2021
Genetically modified non-human animal with human or chimeric GITR
BEIJING BIOCYTOGEN CO LTD0 citations60
UNIV BEIJING TECHNOLOGY
3 patentsUS10570024B2Feb 25, 2020
Method for effluent total nitrogen-based on a recurrent self-organizing RBF neural network
UNIV BEIJING TECHNOLOGY5 citations71
US11346831B2May 31, 2022
Intelligent detection method for biochemical oxygen demand based on a self-organizing recurrent RBF neural network
UNIV BEIJING TECHNOLOGY0 citations50
US11144816B2Oct 12, 2021
Fault identifying method for sludge bulking based on a recurrent RBF neural network
UNIV BEIJING TECHNOLOGY0 citations50